Zoll Biphasic Defibrillator Study Results Show Superiority In AF Treatment
This article was originally published in The Gray Sheet
Executive Summary
Zoll Medical expects to begin shipping automated and manual versions of its biphasic external defibrillator this summer, backed by results from a company-sponsored clinical study of the device in treating atrial fibrillation.
You may also be interested in...
Zoll Banking On M-Series Superiority Claim In Entering Public AED Market
Zoll Medical is expecting the smaller size of its biphasic M-Series automated external defibrillator (AED) combined with FDA-cleared superiority claims over competing devices to result in a sizable chunk of the public access defibrillator market.
Probiotics And Cold Remedies Boost Recordati In 2023
Italy's Recordati saw its OTC sales grow by 10% in 2023 driven by the recovery of the cough & cold market and a growing demand for probiotics.